Fucoidan reduces the toxicities of chemotherapy for patients with unresectable advanced or recurrent colorectal cancer

  • Authors:
    • Masahide Ikeguchi
    • Manabu Yamamoto
    • Yosuke Arai
    • Yoshihiko Maeta
    • Keigo Ashida
    • Kuniyuki Katano
    • Yasunari Miki
    • Takayuki Kimura
  • View Affiliations

  • Published online on: January 21, 2011     https://doi.org/10.3892/ol.2011.254
  • Pages: 319-322
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Combination chemotherapy with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) or irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) has become a standard regimen for advanced or recurrent colorectal cancer. Numerous studies have reported that long-term use of FOLFOX or FOLFIRI leads to better survival for these patients. Thus, control of the toxicity of these drugs may be crucial to prolonging survival. Fucoidan is one of the major sulfated polysaccharides of brown seaweeds and exhibits a wide range of biological activities. In the present study, we analyzed the effect of fucoidan on suppressing the toxicity of anti-cancer drugs. A total of 20 patients with unresectable advanced or recurrent colorectal cancer scheduled to undergo treatment with FOLFOX or FOLFIRI were randomly allocated into a fucoidan treatment group (n=10) and a control group without fucoidan treatment (n=10). Results showed that fucoidan regulated the occurrence of fatigue during chemotherapy. Chemotherapy with fucoidan was continued for a longer period than chemotherapy without fucoidan. Additionally, the survival of patients with fucoidan treatment was longer than that of patients without fucoidan, although the difference was not significant. Thus, fucoidan may enable the continuous administration of chemotherapeutic drugs for patients with unresectable advanced or recurrent colorectal cancer, and as a result, the prognosis of such patients is prolonged.

References

1 

Goldgerg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 22:23–30. 2004. View Article : Google Scholar

2 

Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GER-COR study. J Clin Oncol. 22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI

3 

Japanese Society for Cancer of the Colon and Rectum. Guidelines for Management of Colon Cancer (for Physicians, version 2005). Kanehara & Co., Ltd; Tokyo: 2005

4 

Lee CK, Park KK, Hwang JK, Lee SK and Chung WY: Extract of Prunus persica flesh (PPFE) improves chemotherapeutic efficacy and protects against nephrotoxicity in cisplatin-treated mice. Phytother Res. 23:999–1005. 2009.

5 

Block KI, Koch AC, Mead MN, Tothy PK, Newman RA and Gyllenhaal C: Impact of antioxidant supplementation on chemotherapeutic toxicity: A systematic review of the evidence from randomized controlled trials. Int J Cancer. 123:1227–1239. 2008. View Article : Google Scholar : PubMed/NCBI

6 

Eussen S, Klungel O, Garssen J, et al: Support of drug therapy using functional foods and dietary supplements: focus on statin therapy. Br J Nutr. 103:1260–1277. 2010. View Article : Google Scholar : PubMed/NCBI

7 

Hayashi S, Itoh A, Isoda K, Kondoh M, Kawase M and Yagi K: Fucoidan partly prevents CCl4-induced liver fibrosis. Eur J Pharmacol. 580:380–384. 2008. View Article : Google Scholar : PubMed/NCBI

8 

Yamasaki-Miyamoto Y, Yamasaki M, Tachibana H and Yamada K: Fucoidan induces apoptosis through activation of caspase-8 on human breast cancer MCF-7 cells. J Agric Food Chem. 57:8677–8682. 2009. View Article : Google Scholar : PubMed/NCBI

9 

Saitoh Y, Nagai Y and Miwa N: Fucoidan-Vitamin C complex suppresses tumor invasion through the basement membrane, with scarce injuries to normal or tumor cells, via decreases in oxidative stress and matrix metalloproteinases. Int J Oncol. 35:1183–1189. 2009.

10 

Sugimoto S, Katano K, Kanazawa A, et al: Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients. J Exp Clin Cancer Res. 28:1092009. View Article : Google Scholar : PubMed/NCBI

11 

Therasse P, Arbuck SG, Eisenhauer E, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI

12 

Lévi F, Misset JL, Brienza S, et al: A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer. 69:893–900. 1992.

13 

Choi JI, Raghavendran HRB, Sung NY, et al: Effect of fucoidan on aspirin-induced stomach ulceration in rats. Chem Biol Interact. 183:249–254. 2010. View Article : Google Scholar : PubMed/NCBI

14 

Del Bigio MR, Yan HJ, Campbell TM and Peeling J: Effect of fucoidan treatment on collagenase-induced intracerebral hemorrhage in rats. Neurol Res. 21:415–419. 1999.PubMed/NCBI

15 

Kim KJ, Lee OH, Lee HH and Lee BY: A 4-week repeated oral dose toxicity study of fucoidan from the Sporophyll of Undaria pinnatifida in Sprague-Dawley rats. Toxicology. 267:154–158. 2010. View Article : Google Scholar : PubMed/NCBI

16 

Iop A, Manfredi AM and Bonura S: Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. Ann Oncol. 15:712–720. 2004. View Article : Google Scholar : PubMed/NCBI

17 

Riou D, Colliec-Jouault S, Pinczon du Sel D, et al: Antitumor and antiproliferative effects of a fucan extracted from Ascophyllum nodosum against a non-small-cell bronchopulmonary carcinoma line. Anticancer Res. 16:1213–1218. 1996.PubMed/NCBI

18 

Itoh H, Noda H, Amano H, Zhuaug C, Mizuno T and Ito H: Antitumor activity and immunological properties of marine algal polysaccharides, especially fucoidan, prepared from Sargassum thunbergii of Phaeophyceae. Anticancer Res. 13:2045–2052. 1993.PubMed/NCBI

19 

Maruyama H, Tamauchi H, Hashimoto M and Nakano T: Antitumor activity and immune response of Mekabu fucoidan extracted from Sporophyll of Undaria pinnatifida. In Vivo. 17:245–249. 2003.PubMed/NCBI

20 

Koyanagi S, Tanigawa N, Nakagawa H, Soeda S and Shimeno H: Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities. Biochem Pharmacol. 65:173–179. 2003. View Article : Google Scholar : PubMed/NCBI

21 

Hyun JH, Kim SC, Kang JI, et al: Apoptosis inducing activity of fucoidan in HCT-15 colon carcinoma cells. Biol Pharm Bull. 32:1760–1764. 2009. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

March 2011
Volume 2 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ikeguchi, M., Yamamoto, M., Arai, Y., Maeta, Y., Ashida, K., Katano, K. ... Kimura, T. (2011). Fucoidan reduces the toxicities of chemotherapy for patients with unresectable advanced or recurrent colorectal cancer. Oncology Letters, 2, 319-322. https://doi.org/10.3892/ol.2011.254
MLA
Ikeguchi, M., Yamamoto, M., Arai, Y., Maeta, Y., Ashida, K., Katano, K., Miki, Y., Kimura, T."Fucoidan reduces the toxicities of chemotherapy for patients with unresectable advanced or recurrent colorectal cancer". Oncology Letters 2.2 (2011): 319-322.
Chicago
Ikeguchi, M., Yamamoto, M., Arai, Y., Maeta, Y., Ashida, K., Katano, K., Miki, Y., Kimura, T."Fucoidan reduces the toxicities of chemotherapy for patients with unresectable advanced or recurrent colorectal cancer". Oncology Letters 2, no. 2 (2011): 319-322. https://doi.org/10.3892/ol.2011.254